Abstract:Yue Liu, 1, * Chenguang Yang, 2, * Wenyuan Qi, 1 Zuowei Pei, 2 Wei Xue, 1 Huolan Zhu, 2 Min Dong, 2 Ying Guo, 2 Duanduan Cong, 1 Fang Wang 2 1 Clinical Trial Center, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation, Beijing Hospital, Beijing, People's Republic of China; 2 Internal Medicine-Cardiovascular Department, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Hospital, Beijing, People's Republic of China *These authors contributed equally to this work Correspondence: Fang Wang Email Dabigatran is a novel direct oral anticoagulant agent, whose plasma concentration is closely related to bleeding risk. Genetic polymorphisms can affect the level of plasma dabigatran. The purpose of this study was to understand the relationship between dabigatran-related genes and the plasma level of dabigatran in healthy Chinese subjects after taking a single oral dose. This study was performed with a single-center, single-dose, randomized, open-label, and four-period crossover trial design under both fasting and fed conditions. A total of 106 eligible healthy subjects were enrolled in the study and 104 were genotyped. One-way analysis of variance (ANOVA) was used to compare pharmacokinetic parameters among different genotypes and linear regression was applied to explore the multiplicative interaction between variables. In this study, we found that the genotype frequencies of CES1 rs2244613 and CES1 rs8192935 were significantly different between Chinese and Caucasians, but the genotype frequencies of ABCB1 rs1045642 and ABCB1 rs4148738 were similar in both populations. CES1 rs8192935 were associated with the peak concentration of dabigatran. There was no significant gender difference in the exposure level of dabigatran. Furthermore, food significantly delayed the absorption of dabigatran but had little effect on C max and AUC 0-∞ . Keywords: anticoagulants, dabigatran, genetics, pharmacogenetics, CES1, ABCB1 Dabigatran is a novel direct oral anticoagulant agent (NOAC), 1 first marketed in Europe and then approved by the US Food and Drug Administration (FDA) in 2010 to prevent stroke risk in patients with non-valvular atrial fibrillation (AF). 2 In 2014, an expanded dabigatran indication for preventing deep vein thrombosis and pulmonary thromboembolism was approved. 3 As a specific inhibitor of thrombin, it can reversibly compete to inhibit both free and clot-bound thrombin and the thrombin-induced platelet activation. Dabigatran etexilate is an oral prodrug that can be quickly converted to dabigatran by esterases, especially liver esterase carboxylesterase (CES) 1. Dabigatran etexilate is a substrate of the P-glycoprotein (P-gp), encoded by the adenosine-triphosphate (ATP)-binding cassette sub-family B member (ABCB)1 genes. Potent P-gp inhibitors could increase the bioavailability of dabigatran by 12% to 23%. 1 , 4 , 5 Studies indicated that dabigatran had a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. However, wide inter-individual variability in pharmacokinetic and pharmacodynamic responses to dabigatran have recently been reported. 6 , 7 Furthermore, dabigatran was also observed to cause clinical bleeding. 8 It has been confirmed that genetic polymorphisms affect the plasma level of dabigatran, 6 , 9 , 10 which is closely associated with bleeding risk. The purpose of this study was to explore the relationship between single-nucleotide polymorphisms (SNPs) of dabigatran-related genes and the plasma level of dabigatran in healthy Chinese subjects after taking a single oral dose. We studied the relationship between the allele frequencies of single nucleotide polymorphisms in dabigatran-related genes and pharmacokinetic parameters in Chinese and compared the allele frequencies of these SNPs between Chinese and Caucasians. We hope that our findings could provide a basis for the safe use of dabigatran in future clinical practice. The study was designed following the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines, and other related guiding principles. The study protocol was reviewed and approved by the independent ethics committee of Beijing Hospita -Abstract Truncated-

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study

Study on the Correlation Between CETP TaqIB,KCNE1 S38G and Enos T-786C Gene Polymorphisms for Predisposition and Non-Valvular Atrial Fibrillation

SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation.

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation

Effect of genetic variants on bleeding with rivaroxaban in pulmonary embolism patients: A multicenter prospective cohort study

Candidate Gene and Pathway Analyses Identifying Genetic Variations Associated with Prasugrel Pharmacokinetics and Pharmacodynamics.

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

PROK2, HRNR, and FIG4 As Potential Genetic Biomarkers of High Bleeding Propensity in East Asian Patients with Acute Coronary Syndrome Using Ticagrelor

Association between CES1 rs2244613 and the pharmacokinetics and safety of dabigatran: Meta-analysis and quantitative trait loci analysis

Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population

Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants

Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Identification of Genetic Biomarkers Associated with Pharmacokinetics and Pharmacodynamics of Apixaban in Chinese Healthy Volunteers.

Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation

Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation

Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry

The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study